|
Video: What is a Stock Split?
|
|
Pharming Group is a global, commercial stage biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. Co.'s primary portfolio is its recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down-regulates the complement cascade in order to control swelling in affected tissues. Co.'s primary product, RUCONEST® is a plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema attacks. Co. is also developing rhC1INH for subsequent indications, including pre-eclampsia, and acute kidney injury. According to our Pharming Group stock split history records, Pharming Group has had 0 splits. | |
|
Pharming Group (PHAR) has 0 splits in our Pharming Group stock split history database.
Looking at the Pharming Group stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Pharming Group shares, starting with a $10,000 purchase of PHAR, presented on a split-history-adjusted basis factoring in the complete Pharming Group stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/24/2020 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$15.59 |
|
End price/share: |
$9.80 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-37.14% |
|
Average Annual Total Return: |
-12.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,285.55 |
|
Years: |
3.34 |
|
|
|
|
|